Elsevier

Clinical Therapeutics

Volume 24, Issue 3, March 2002, Pages 378-396
Clinical Therapeutics

Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records

https://doi.org/10.1016/S0149-2918(02)85040-8Get rights and content

Abstract

Background: The antihyperglycemic effects of pioglitazone hydrochloride and rosiglitazone maleate are well documented. The results of clinical trials and observational studies have suggested, however, that there are individual differences in the effects of these drugs on blood lipid levels.

Objective: The present study evaluated the effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus.

Methods: This was a retrospective review of randomly selected medical records from 605 primary care practices in the United States in which adults with type 2 diabetes received pioglitazone or rosiglitazone between August 1, 1999, and August 31, 2000. The outcome measures were mean changes in serum concentrations of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and glycosylated hemoglobin (HbA1c) values.

Results: Treatment with pioglitazone was associated with a reduction in mean TG of 55.17 mg/dL, a reduction in TC of 8.45 mg/dL, an increase in HDL-C of 2.65 mg/dL, and a reduction in LDL-C of 5.05 mg/dL. Treatment with rosiglitazone was associated with a reduction in mean TG of 13.34 mg/dL, an increase in TC of 4.81 mg/dL, a reduction in HDL-C of 0.12 mg/dL, and an increase in LDL-C of 3.56 mg/dL. With the exception of HDL-C, the differences in mean changes in lipid parameters between treatment groups were statistically significantly (P < 0.001, pioglitazone vs rosiglitazone). Reductions in HbA1c were statistically equivalent between treatments (1.04% pioglitazone, 1.18% rosiglitazone).

Conclusions: Treatment with pioglitazone was associated with greater beneficial effects on blood lipid levels than treatment with rosiglitazone, whereas glycemic control was equivalent between the 2 treatments.

References (53)

  • JM Olefsky

    Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

    J Clin Invest

    (2000)
  • PB Watkins et al.

    Hepatic dysfunction associated with troglitazone

    N Engl J Med

    (1998)
  • A Shibuya et al.

    An autopsy case of troglitazone-induced fulminant hepatitis

    Diabetes Care

    (1998)
  • N Gitlin et al.

    Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone

    Ann Intern Med

    (1998)
  • (1999)
  • NB Glazer et al.

    Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4

    Br Med J

    (2001)
  • K Maeda

    Hepatocellular injury in a patient receiving pioglitazone

    Ann Intern Med

    (2001)
  • (2001)
  • J Al-Salman et al.

    Hepatocellular injury in a patient receiving rosiglitazone. A case report

    Ann Intern Med

    (2000)
  • LM Forman et al.

    Hepatic failure in a patient taking rosiglitazone

    Ann Intern Med

    (2000)
  • J Freid et al.

    Rosiglitazone and hepatic failure

    Ann Intern Med

    (2000)
  • WL Isley et al.

    Rosiglitazone and liver failure

    Ann Intern Med

    (2000)
  • RS Ravinuthala et al.

    Rosiglitazone toxicity

    Ann Intern Med

    (2000)
  • S Rosenblatt et al.

    The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

    Coron Artery Dis

    (2001)
  • S Aronoff et al.

    Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study

    Diabetes Care

    (2000)
  • HE Lebovitz et al.

    Rosiglitazone monotherapy is effective in patients with type 2 diabetes

    J Clin Endocrinol Metab

    (2001)
  • Cited by (165)

    • Dietary supplementation with pioglitazone hydrochloride and L-carnosine improves the growth performance, muscle fatty acid profiles and shelf life of yellow-feathered broiler chickens

      2021, Animal Nutrition
      Citation Excerpt :

      Excessive abdominal fat content can negatively affect feed efficiency and carcass performance. The abdominal fat yield decreased with PGZ supplementation, which was more beneficial for IMF deposition (Boyle et al., 2002; Cai et al., 2011). Unlike abdominal fat, IMF is a favorable trait of great economic importance and has a positive effect on the tenderness, flavor, and juiciness of meat (Bonny et al., 2015; Gerbens et al., 2001).

    • Effect of the acute and chronic administration of Lupinus albus β-conglutin on glycaemia, circulating cholesterol, and genes potentially involved

      2021, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Besides, serum triglyceride levels decreased, whereas total serum cholesterol increased. El-Batran et al. reported that rosiglitazone lowered cholesterol and triglyceride levels in rats induced to diabetes by STZ [44], our results, however, agree with those observed in patients treated with rosiglitazone [45]. Nonetheless, our findings should be interpreted with caution since the effects of rosiglitazone are dose-dependent [46].

    View all citing articles on Scopus
    View full text